Baidu
map

英国NICE推荐帕妥珠单抗Perjeta用于治疗新的乳腺癌适应症

2019-02-18 不详 MedSci原创

英国国家健康与护理研究所(NICE)草案指南推荐罗氏公司的Perjeta(帕妥珠单抗)用于治疗新的乳腺癌适应症。该建议用于治疗已经接受过手术并且其癌症已经扩散至其淋巴结(淋巴结阳性疾病)的早期HER2阳性乳腺癌患者。

英国国家健康与护理研究所(NICE)草案指南推荐罗氏公司的Perjeta(帕妥珠单抗)用于治疗新的乳腺癌适应症,即已经接受过手术治疗并且已扩散至淋巴结(淋巴结阳性)的早期HER2阳性乳腺癌患者。

Perjeta是通过结合HER2,阻滞了HER2与其它HER受体的杂二聚,来减缓了肿瘤的生长。

Perjeta与Herceptin(曲妥珠单抗)和化疗药物联用已被推荐用于术前治疗早期HER2阳性乳腺癌患者(新佐剂使用)。同时,Perjeta也与Herceptin和Taxotere(多西紫杉醇)联合用于治疗HER2阳性的、初始治疗后复发或已从乳房扩散到身体的其他部位的乳腺癌患者。

实验结果表明,Perjeta与Herceptin(曲妥珠单抗)和化疗药物联用用于术后治疗(辅助使用)可增加癌症未扩散人群的比例。

NICE健康技术评估中心主任Meindert Boysen说:"该实验结果意味着患有高风险类型乳腺癌的患者现在又拥有了一种新的治疗方案"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1727895, encodeId=9d671e2789589, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 30 21:21:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289040, encodeId=cd38128904036, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336774, encodeId=be101336e7451, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521625, encodeId=48c615216257e, content=<a href='/topic/show?id=18bb8e08622' target=_blank style='color:#2F92EE;'>#英国NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87086, encryptionId=18bb8e08622, topicName=英国NICE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ce711379167, createdName=lvygwyt2785, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-04-30 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1727895, encodeId=9d671e2789589, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 30 21:21:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289040, encodeId=cd38128904036, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336774, encodeId=be101336e7451, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521625, encodeId=48c615216257e, content=<a href='/topic/show?id=18bb8e08622' target=_blank style='color:#2F92EE;'>#英国NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87086, encryptionId=18bb8e08622, topicName=英国NICE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ce711379167, createdName=lvygwyt2785, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-20 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1727895, encodeId=9d671e2789589, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 30 21:21:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289040, encodeId=cd38128904036, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336774, encodeId=be101336e7451, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521625, encodeId=48c615216257e, content=<a href='/topic/show?id=18bb8e08622' target=_blank style='color:#2F92EE;'>#英国NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87086, encryptionId=18bb8e08622, topicName=英国NICE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ce711379167, createdName=lvygwyt2785, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1727895, encodeId=9d671e2789589, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 30 21:21:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289040, encodeId=cd38128904036, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336774, encodeId=be101336e7451, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521625, encodeId=48c615216257e, content=<a href='/topic/show?id=18bb8e08622' target=_blank style='color:#2F92EE;'>#英国NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87086, encryptionId=18bb8e08622, topicName=英国NICE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ce711379167, createdName=lvygwyt2785, createdTime=Wed Feb 20 07:21:00 CST 2019, time=2019-02-20, status=1, ipAttribution=)]

相关资讯

JCO:认知行为疗法对乳腺癌治疗诱导的更年期症状的疗效

最近,在患有治疗引起的更年期症状的乳腺癌幸存者中,研究人员评估了基于互联网的认知行为疗法(iCBT),无论是否有治疗师支持,对潮热和盗汗(HF / NS),更年期症状的总体水平(主要结果),睡眠质量,HF / NS频率,性功能,心理困扰和与健康相关的生活质量的影响。

NEJM:Trastuzumab emtansine治疗残留浸润型乳腺癌效果显著

研究认为,对于在新辅助化疗后存在浸润性疾病残留的HER2阳性乳腺癌患者,接受抗体偶联型曲妥珠单抗可将患者疾病复发及死亡风险降低50%

NCCN临床实践指南:乳腺癌(2018.V4)

2019年2月,美国国家综合癌症网络(NCCN)发布了乳腺癌管理指南2018年第4版,指南主要内容涉及: 指南更新摘要 非浸润性乳腺癌 浸润性乳腺癌 特殊考虑

Menopause:持续潮热可增加女性乳腺癌风险

潮热是女性围绝经期所面临的重要困扰,其到底对于女性健康有着哪些严重危害?近期,一项有关女性健康倡议(WHI)最新分析结果发现,持续潮热可增加绝经后女性罹患乳腺癌的风险,但并不增加其乳腺癌死亡风险。

Baidu
map
Baidu
map
Baidu
map